Latest Isis Pharmaceuticals (ISIS) Headlines
Appointments, Regulatory Approvals, Conference Participation Schedule, Acquisitions, and Increased Stake - Analyst Notes on Perrigo, Zoetis, ISIS, GSK, and AstraZeneca
PR Newswire - 1 hr 34 mins ago
Today, Analysts Review released its analysts' notes regarding Perrigo Company (NYSE: PRGO), Zoetis Inc. (NYSE: ZTS), ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS), GlaxoSmithKline plc (NYSE: GSK), and AstraZeneca plc (NYSE: AZN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
3 Ways You Can Be a Better Health-Care Investor Than Warren Buffett
Sean Williams, The Motley Fool - Motley Fool - Sun Mar 09, 1:03PM CDT
Behind only three other people on this planet -- Bill Gates, Carlos Slim, and Amancio Ortega -- stands Warren Buffett with $58.2 billion in accumulated wealth, according to Forbes ' latest rankings of the world's richest people. Buffett, perhaps...
Isis Pharmaceuticals Falls 1.99% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Mar 07, 4:47PM CST
Isis Pharmaceuticals (NASDAQ:ISIS) traded in a range yesterday that spanned from a low of $50.00 to a high of $53.32. Yesterday, the shares fell 2.0%, which took the trading range below the 3-day low of $51.51 on volume of 2.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Shares of ISIS Up 90.1% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Mar 06, 9:37AM CST
SmarTrend identified an Uptrend for Isis Pharmaceuticals (NASDAQ:ISIS) on September 5th, 2013 at $28.67. In approximately 6 months, Isis Pharmaceuticals has returned 90.06% as of today's recent price of $54.48.
Isis Pharmaceuticals to Present at the Barclays Global Healthcare Conference
PR Newswire - Thu Mar 06, 6:00AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Barclays Global Healthcare Conference on Thursday, March 13, 2014 at 9:00 a.m. ET in Miami, FL.
Why Isis Pharmaceuticals Continues to Impress
Cory Renauer, The Motley Fool - Motley Fool - Wed Mar 05, 1:30PM CST
Over the past twelve months Isis Pharmaceuticals has been on a tear both at the deal table and in the market. At $51, Isis is still up more than 230% over the past twelve months. The company reported fourth quarter 2013 earnings...
Isis Pharmaceuticals, Inc. (ISIS) in Focus: Stock up 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 7:44AM CST
Isis Pharmaceuticals, Inc. was a big mover last session, as the company saw its shares surge 9% on the day.
Jim Cramer's 'Mad Money' Recap: Stocks on Sale
at The Street - Tue Mar 04, 7:08PM CST
It was Mardi Gras on Wall Street today after Monday's drop, which created a one-day sale on great stocks, Cramer says.
Why Zynga Inc., Isis Pharmaceuticals, and Vipshop Holdings Ltd. Are Today's 3 Best Stocks
Dan Carroll, The Motley Fool - Motley Fool - Tue Mar 04, 4:15PM CST
The S&P 500 's had a whale of a year so far in 2014 after a sluggish start to the year, and it put on quite a show today after Monday's shellacking. The S&P notched a new record high at the market close today, gaining 1.3% on a day when...
Isis Pharma Slips on Wider-Than-Expected Q4 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 2:06PM CST
Fourth quarter 2013 loss was 4 cents wider-than-expected.
Concise Analysis of the International Bolus Injectors Market, 2014 - 2024
M2 - Tue Mar 04, 6:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/jpbd3g/bolus_injectors) has announced the addition of the "Concise Analysis of the International Bolus Injectors Market, 2014 - 2024" report to their offering. The injectable drug delivery market holds significant potential for the future. From conventional syringes with vials and painful needles to the modern-day pre-filled syringes, pen-injectors, needle free injectors and auto-injectors, the injectable drug delivery devices market has come a long way. Taking the concept of self-injectors to a new stratum, Bolus Injectors' have surfaced recently. Also known as non-insulin patch pumps, these devices not only offer a range of benefits to the end users but also provide a number of additional benefits to other stakeholders in the industry. One of the main drivers for the perceived growth of bolus injectors is the large number of biologics currently under development. A majority of these molecules are highly viscous and are required to be delivered in volumes of greater than 1 ml. The absence of devices which can safely administer these drugs is currently a big unmet need in the market. However, the early signs are encouraging. Despite the uncertainties related to the device development and approval, many companies are investing time, money and resources to develop novel devices. Key Topics Covered: 1. Executive Summary 2. Introduction 3. Overview And Market Background 4. Target Drugs For Bolus Injectors 5. Product Profiles 6. Market Size And Forecast 7. Swot Analysis 8. Company Profiles 9. Interview Transcripts 10. Conclusion 11. Appendix 1: Tables 12. Appendix 2: List Of Companies Companies Mentioned: - AbbVie - Abbott - BMS - Boehringer Ingelheim - Calando Pharmaceuticals - Calibra Medical - Dekkun - Denderon - Eisai - Elcam Medical - Eli Lilly - Five Prime Therapeutics - Future Injection Technologies - Genentech - Genethon - Isis Pharmaceuticals - J&J - Janssen Biotech - Kyowa Hakko Kirin - Lincoln Medical Limited - MacroGenics - Nuron Biotech - Octapharma - OncoGenex Technologies - Pfizer - PhaseBio Pharmaceuticals - Roche - SteadyMed Therapeutics - Synageva BioPharma - TaiMed Biologics - Takeda Pharmaceuticals - VBL Therapeutics - West Pharmaceutical Services - Xbiotech - Ypsomed - ZZ Biotech For more information visit http://www.researchandmarkets.com/research/jp..._injectors
Jim Cramer's Top Stock Picks: BIDU GNC VSI ISIS
at The Street - Tue Mar 04, 5:00AM CST
Isis Pharmaceuticals is one of Cramer's favorites and he's bullish on Baidu.
Jim Cramer's 'Mad Money' Recap: Stop Panicking
at The Street - Mon Mar 03, 7:08PM CST
Ukraine is just another in a long list of foreign crises that have the markets operating on emotion instead of logic, Cramer says.
ISIS Pharmaceuticals Earns $1 Million from GSK for Advancing ISIS-TTR Rx
PR Newswire - Mon Mar 03, 6:00AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $1 million milestone payment from GlaxoSmithKline (GSK) related to the initiation of an open-label extension study of ISIS-TTRRx, which is being offered to those patients with familial amyloid polyneuropathy (FAP) who have completed dosing in the Phase 2/3 study of ISIS-TTRRx.
Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2014 Report
M2 - Mon Mar 03, 2:42AM CST
Research and Markets (http://www.researchandmarkets.com/research/t59t59/spinal_muscular) has announced the addition of the "Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2014" report to their offering. 'Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2014', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Spinal Muscular Atrophy (SMA) , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Spinal Muscular Atrophy (SMA) . Spinal Muscular Atrophy (SMA) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Spinal Muscular Atrophy (SMA) . - A review of the Spinal Muscular Atrophy (SMA) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Spinal Muscular Atrophy (SMA) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Spinal Muscular Atrophy (SMA) Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Drug Profiles olesoxime - Drug Profile valproate sodium [levocarnitine] - Drug Profile ISIS-SMNRx - Drug Profile sodium phenylbutyrate - Drug Profile PF-06687859 - Drug Profile SMN-2 - Drug Profile MotorGraft - Drug Profile AAV9-SMN Gene Therapy - Drug Profile Motor Neuron Precursor Cells - Drug Profile PTK-SMA-2 - Drug Profile NXD-30001 - Drug Profile DNA Oligonucleotides For Spinal Muscular Atrophy - Drug Profile RE-003 - Drug Profile fasudil - Drug Profile Drug for Spinal Muscular Atrophy - Drug Profile ND-602 - Drug Profile RNase H-Active Antisense Oligos - Drug Profile Indoprofren Analog - Drug Profile Agrin Biologic For SMA - Drug Profile sodium phenylbutyrate - Drug Profile Drugs for Motor Neuron Diseases - Drug Profile PMO-25 - Drug Profile INT-41 - Drug Profile Antisense Molecules - Drug Profile Featured News & Press Releases Appendix Companies Mentioned Genzyme Corporation F. Hoffmann-La Roche Ltd. Isis Pharmaceuticals, Inc. Pfizer Inc. Paratek Pharmaceuticals, Inc. Neurotune AG Trophos SA Nexgenix Pharmaceuticals, LLC Genethon Vybion, Inc. California Stem Cell, Inc. OrphageniX, Inc. Retrophin, LLC Neurodyn Inc. Cellular Biomedicine Group, Inc. gmp-orphan SAS For more information visit http://www.researchandmarkets.com/research/t5...l_muscular About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
SmarTrend Watching for Potential Rebound in Shares of Isis Pharmaceuticals After 9.53% Loss
Comtex SmarTrend(R) - Fri Feb 28, 5:13PM CST
Isis Pharmaceuticals (NASDAQ:ISIS) traded in a range yesterday that spanned from a low of $48.51 to a high of $58.31. Yesterday, the shares fell 9.5%, which took the trading range below the 3-day low of $55.05 on volume of 3.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Isis Pharmaceuticals (ISIS) Is Water-Logged And Getting Wetter Today
at The Street - Fri Feb 28, 1:29PM CST
Trade-Ideas LLC identified Isis Pharmaceuticals (ISIS) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
Isis Pharmaceuticals Q4 Revenue More Than Doubles; Loss Widens Anyway
Sean Williams, The Motley Fool - Motley Fool - Fri Feb 28, 11:24AM CST
Antisense drug developer Isis Pharmaceuticals released its fourth-quarter earnings results before the opening bell this morning, pointing to a sizable uptick in recognized revenue, but also seeing its losses widen significantly from the year-ago...
Isis Reports Financial Results And Highlights For 2013
PR Newswire - Fri Feb 28, 7:30AM CST
Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its 2013 financial results and reviewed the highlights of the year. Isis ended the year in a strong financial position and outperformed both its pro forma net operating loss (NOL) guidance and its cash guidance for the year. For the year ended December 31, 2013, Isis had an NOL of $40.2 million compared to $60.4 million for 2012. Isis' strong financial performance in 2013 is the result of the Company's successful execution of its business strategy. Isis added a substantial amount of cash to its balance sheet in 2013, ending the year with $657 million. The increase in the Company's cash position was primarily due to the significant amount of cash received from its partners as well as the net proceeds from the equity offering it completed in 2013. On a GAAP basis, Isis reported a loss from operations of $19.9 million and $51.7 million for the three and twelve months ended December 31, 2013, respectively, compared to $26.1 million and $68.9 million for the same periods in 2012.
Appointments, Regulatory Approvals, Conference Participation Schedule, Acquisitions, and Increased Stake - Analyst Notes on Perrigo, Zoetis, ISIS, GSK, and AstraZeneca
PR Newswire - 1 hr 34 mins ago
Today, Analysts Review released its analysts' notes regarding Perrigo Company (NYSE: PRGO), Zoetis Inc. (NYSE: ZTS), ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS), GlaxoSmithKline plc (NYSE: GSK), and AstraZeneca plc (NYSE: AZN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
3 Ways You Can Be a Better Health-Care Investor Than Warren Buffett
Sean Williams, The Motley Fool - Motley Fool - Sun Mar 09, 1:03PM CDT
Behind only three other people on this planet -- Bill Gates, Carlos Slim, and Amancio Ortega -- stands Warren Buffett with $58.2 billion in accumulated wealth, according to Forbes ' latest rankings of the world's richest people. Buffett, perhaps...
Isis Pharmaceuticals Falls 1.99% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Mar 07, 4:47PM CST
Isis Pharmaceuticals (NASDAQ:ISIS) traded in a range yesterday that spanned from a low of $50.00 to a high of $53.32. Yesterday, the shares fell 2.0%, which took the trading range below the 3-day low of $51.51 on volume of 2.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Shares of ISIS Up 90.1% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Mar 06, 9:37AM CST
SmarTrend identified an Uptrend for Isis Pharmaceuticals (NASDAQ:ISIS) on September 5th, 2013 at $28.67. In approximately 6 months, Isis Pharmaceuticals has returned 90.06% as of today's recent price of $54.48.
Isis Pharmaceuticals to Present at the Barclays Global Healthcare Conference
PR Newswire - Thu Mar 06, 6:00AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Barclays Global Healthcare Conference on Thursday, March 13, 2014 at 9:00 a.m. ET in Miami, FL.
Why Isis Pharmaceuticals Continues to Impress
Cory Renauer, The Motley Fool - Motley Fool - Wed Mar 05, 1:30PM CST
Over the past twelve months Isis Pharmaceuticals has been on a tear both at the deal table and in the market. At $51, Isis is still up more than 230% over the past twelve months. The company reported fourth quarter 2013 earnings...
Isis Pharmaceuticals, Inc. (ISIS) in Focus: Stock up 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 7:44AM CST
Isis Pharmaceuticals, Inc. was a big mover last session, as the company saw its shares surge 9% on the day.
Jim Cramer's 'Mad Money' Recap: Stocks on Sale
at The Street - Tue Mar 04, 7:08PM CST
It was Mardi Gras on Wall Street today after Monday's drop, which created a one-day sale on great stocks, Cramer says.
Why Zynga Inc., Isis Pharmaceuticals, and Vipshop Holdings Ltd. Are Today's 3 Best Stocks
Dan Carroll, The Motley Fool - Motley Fool - Tue Mar 04, 4:15PM CST
The S&P 500 's had a whale of a year so far in 2014 after a sluggish start to the year, and it put on quite a show today after Monday's shellacking. The S&P notched a new record high at the market close today, gaining 1.3% on a day when...
Isis Pharma Slips on Wider-Than-Expected Q4 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 2:06PM CST
Fourth quarter 2013 loss was 4 cents wider-than-expected.
Concise Analysis of the International Bolus Injectors Market, 2014 - 2024
M2 - Tue Mar 04, 6:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/jpbd3g/bolus_injectors) has announced the addition of the "Concise Analysis of the International Bolus Injectors Market, 2014 - 2024" report to their offering. The injectable drug delivery market holds significant potential for the future. From conventional syringes with vials and painful needles to the modern-day pre-filled syringes, pen-injectors, needle free injectors and auto-injectors, the injectable drug delivery devices market has come a long way. Taking the concept of self-injectors to a new stratum, Bolus Injectors' have surfaced recently. Also known as non-insulin patch pumps, these devices not only offer a range of benefits to the end users but also provide a number of additional benefits to other stakeholders in the industry. One of the main drivers for the perceived growth of bolus injectors is the large number of biologics currently under development. A majority of these molecules are highly viscous and are required to be delivered in volumes of greater than 1 ml. The absence of devices which can safely administer these drugs is currently a big unmet need in the market. However, the early signs are encouraging. Despite the uncertainties related to the device development and approval, many companies are investing time, money and resources to develop novel devices. Key Topics Covered: 1. Executive Summary 2. Introduction 3. Overview And Market Background 4. Target Drugs For Bolus Injectors 5. Product Profiles 6. Market Size And Forecast 7. Swot Analysis 8. Company Profiles 9. Interview Transcripts 10. Conclusion 11. Appendix 1: Tables 12. Appendix 2: List Of Companies Companies Mentioned: - AbbVie - Abbott - BMS - Boehringer Ingelheim - Calando Pharmaceuticals - Calibra Medical - Dekkun - Denderon - Eisai - Elcam Medical - Eli Lilly - Five Prime Therapeutics - Future Injection Technologies - Genentech - Genethon - Isis Pharmaceuticals - J&J - Janssen Biotech - Kyowa Hakko Kirin - Lincoln Medical Limited - MacroGenics - Nuron Biotech - Octapharma - OncoGenex Technologies - Pfizer - PhaseBio Pharmaceuticals - Roche - SteadyMed Therapeutics - Synageva BioPharma - TaiMed Biologics - Takeda Pharmaceuticals - VBL Therapeutics - West Pharmaceutical Services - Xbiotech - Ypsomed - ZZ Biotech For more information visit http://www.researchandmarkets.com/research/jp..._injectors
Jim Cramer's Top Stock Picks: BIDU GNC VSI ISIS
at The Street - Tue Mar 04, 5:00AM CST
Isis Pharmaceuticals is one of Cramer's favorites and he's bullish on Baidu.
Jim Cramer's 'Mad Money' Recap: Stop Panicking
at The Street - Mon Mar 03, 7:08PM CST
Ukraine is just another in a long list of foreign crises that have the markets operating on emotion instead of logic, Cramer says.
ISIS Pharmaceuticals Earns $1 Million from GSK for Advancing ISIS-TTR Rx
PR Newswire - Mon Mar 03, 6:00AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $1 million milestone payment from GlaxoSmithKline (GSK) related to the initiation of an open-label extension study of ISIS-TTRRx, which is being offered to those patients with familial amyloid polyneuropathy (FAP) who have completed dosing in the Phase 2/3 study of ISIS-TTRRx.
Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2014 Report
M2 - Mon Mar 03, 2:42AM CST
Research and Markets (http://www.researchandmarkets.com/research/t59t59/spinal_muscular) has announced the addition of the "Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2014" report to their offering. 'Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2014', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Spinal Muscular Atrophy (SMA) , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Spinal Muscular Atrophy (SMA) . Spinal Muscular Atrophy (SMA) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Spinal Muscular Atrophy (SMA) . - A review of the Spinal Muscular Atrophy (SMA) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Spinal Muscular Atrophy (SMA) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Spinal Muscular Atrophy (SMA) Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Drug Profiles olesoxime - Drug Profile valproate sodium [levocarnitine] - Drug Profile ISIS-SMNRx - Drug Profile sodium phenylbutyrate - Drug Profile PF-06687859 - Drug Profile SMN-2 - Drug Profile MotorGraft - Drug Profile AAV9-SMN Gene Therapy - Drug Profile Motor Neuron Precursor Cells - Drug Profile PTK-SMA-2 - Drug Profile NXD-30001 - Drug Profile DNA Oligonucleotides For Spinal Muscular Atrophy - Drug Profile RE-003 - Drug Profile fasudil - Drug Profile Drug for Spinal Muscular Atrophy - Drug Profile ND-602 - Drug Profile RNase H-Active Antisense Oligos - Drug Profile Indoprofren Analog - Drug Profile Agrin Biologic For SMA - Drug Profile sodium phenylbutyrate - Drug Profile Drugs for Motor Neuron Diseases - Drug Profile PMO-25 - Drug Profile INT-41 - Drug Profile Antisense Molecules - Drug Profile Featured News & Press Releases Appendix Companies Mentioned Genzyme Corporation F. Hoffmann-La Roche Ltd. Isis Pharmaceuticals, Inc. Pfizer Inc. Paratek Pharmaceuticals, Inc. Neurotune AG Trophos SA Nexgenix Pharmaceuticals, LLC Genethon Vybion, Inc. California Stem Cell, Inc. OrphageniX, Inc. Retrophin, LLC Neurodyn Inc. Cellular Biomedicine Group, Inc. gmp-orphan SAS For more information visit http://www.researchandmarkets.com/research/t5...l_muscular About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
SmarTrend Watching for Potential Rebound in Shares of Isis Pharmaceuticals After 9.53% Loss
Comtex SmarTrend(R) - Fri Feb 28, 5:13PM CST
Isis Pharmaceuticals (NASDAQ:ISIS) traded in a range yesterday that spanned from a low of $48.51 to a high of $58.31. Yesterday, the shares fell 9.5%, which took the trading range below the 3-day low of $55.05 on volume of 3.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Isis Pharmaceuticals (ISIS) Is Water-Logged And Getting Wetter Today
at The Street - Fri Feb 28, 1:29PM CST
Trade-Ideas LLC identified Isis Pharmaceuticals (ISIS) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
Isis Pharmaceuticals Q4 Revenue More Than Doubles; Loss Widens Anyway
Sean Williams, The Motley Fool - Motley Fool - Fri Feb 28, 11:24AM CST
Antisense drug developer Isis Pharmaceuticals released its fourth-quarter earnings results before the opening bell this morning, pointing to a sizable uptick in recognized revenue, but also seeing its losses widen significantly from the year-ago...
Isis Reports Financial Results And Highlights For 2013
PR Newswire - Fri Feb 28, 7:30AM CST
Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its 2013 financial results and reviewed the highlights of the year. Isis ended the year in a strong financial position and outperformed both its pro forma net operating loss (NOL) guidance and its cash guidance for the year. For the year ended December 31, 2013, Isis had an NOL of $40.2 million compared to $60.4 million for 2012. Isis' strong financial performance in 2013 is the result of the Company's successful execution of its business strategy. Isis added a substantial amount of cash to its balance sheet in 2013, ending the year with $657 million. The increase in the Company's cash position was primarily due to the significant amount of cash received from its partners as well as the net proceeds from the equity offering it completed in 2013. On a GAAP basis, Isis reported a loss from operations of $19.9 million and $51.7 million for the three and twelve months ended December 31, 2013, respectively, compared to $26.1 million and $68.9 million for the same periods in 2012.
